LP
SABSW icon

LMR Partners’s SAB Biotherapeutics Warrant SABSW Stock Holding History

LMR Partners’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1K Buy
+539,588
New +$18.6K ﹤0.01% 1358
2025
Q4 		– Sell
-539,588
Closed -$12.6K – 1695
2025
Q3 		$12.6K Hold
539,588
– – ﹤0.01% 1368
2025
Q2 		$18K Hold
539,588
– – ﹤0.01% 1264
2025
Q1 		$18.8K Hold
539,588
– – ﹤0.01% 1241
2024
Q4 		$40.6K Buy
+539,588
New +$32.5K ﹤0.01% 1049
2024
Q3 		– Sell
-539,588
Closed -$20.2K – 1485
2024
Q2 		$25.6K Hold
539,588
– – ﹤0.01% 970
2024
Q1 		$21K Hold
539,588
– – ﹤0.01% 1029
2023
Q4 		$16.3K Hold
539,588
– – ﹤0.01% 844
2023
Q3 		$37.8K Hold
539,588
– – ﹤0.01% 742
2023
Q2 		$56.3K Hold
539,588
– – ﹤0.01% 658
2023
Q1 		$237K Hold
539,588
– – ﹤0.01% 839
2022
Q4 		$318K Buy
539,588
+152,000
+39% +$9.27K 0.01% 946
2022
Q3 		$272K Buy
387,588
+29,239
+8% +$3.49K 0.01% 974
2022
Q2 		$520K Buy
358,349
+21,067
+6% +$4.8K 0.01% 901
2022
Q1 		$1.27M Buy
337,282
+320,982
+1,969% +$271K 0.01% 723
2021
Q4 		$127K Buy
+16,300
New +$29.9K ﹤0.01% 1104

Other funds holding SABSW

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

LMR Partners's SABSW Position: Q1 2026 in Review

LMR Partners opened a new position in SAB Biotherapeutics Warrant (SABSW) in Q1 2026: 539,588 shares worth $14.1K. The stake represents ﹤0.01% of the portfolio and ranks #1358 among its holdings. This is a return to the name: LMR Partners previously reported a position in SABSW as recently as Q3 2025.

LMR Partners first reported a position in SABSW in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.27M in Q1 2022. 6 funds tracked by Wall St. Rank hold SABSW as of Q1 2026.

  • LMR Partners held 539,588 shares of SAB Biotherapeutics Warrant worth $14.1K as of Q1 2026.
  • SAB Biotherapeutics Warrant was a new LMR Partners position in Q1 2026.
  • SAB Biotherapeutics Warrant made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1358 holding.
  • LMR Partners first reported a position in SAB Biotherapeutics Warrant in Q4 2021 and has held it in 16 quarters since.
  • LMR Partners's SAB Biotherapeutics Warrant position peaked at $1.27M in Q1 2022.
  • 6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.